康哲药业(00867.HK) 公布,磷酸芦可替尼乳膏(白癜风适应症)新药上市许可申请已获中国国家药品监督管理局受理。2022年12月,公司附属康哲美丽与Incyte订立合作和许可协议,获得在内地、香港、澳门、台湾及东南亚11国研发、注册及商业化芦可替尼乳膏的独家许可权利。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-24 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.